News Acomplia Zimulti

News Acomplia Zimulti (Rimonabant -Rip)

Subscribe via Email

Sanofi Allowed to Inform Patients Taking Acomplia That It Aids Blood Sugar Control

The European Commission has decided to let Sanofi-Aventis inform patients taking diet drug Acomplia (rimonabant) that the pill may also help in diabetic blood sugar control, but that does not mean it is approved to be prescribed as a diabetes drug.

The announcement, which ratified an earlier decision by the European Medicines Agency (EMEA), means only that Sanofi can include news of results from a small phase IIIb trial on the insert that is included ib packages of Acomplia (rimonabant) sold in European Union countries.

The current prescribing indications, approved by the European Commission in the summer of 2006, authorize use of Acomplia (rimonabant) in Europe as an adjunct to diet and exercise for treatment of obese patients or overweight patients with associated risk factors such as type 2 diabetes or dyslipidaemia.

The drug is not approved for sale in the United States, where Sanofi had hoped to sell it as “;Zimulti” , and the company pulled back its application after an FDA advisory panel expressed concern over rimonabant’s depressive and suicidal side-effects..

But Sanofi has said it hopes, based on eight trials now underway, to submit Acomplia (rimonabant) for worldwide approval as a treatment for type 2 diabetes in 2009, and the European decision to allow inclusion of results from a diabetes trial on the insert suggests more off-label use of the drug Acomplia (rimonabant) to treat diabetes may occur in the meantime.

The results come from the so-called SERENADE trial, which compared use of Acomplia (rimonabant) to improve blood sugar control (as indicated by the patient’s HbA1c level, a measure of glucose control) in 276 newly diagnosed type 2 diabetic patients who had not yet been treated with any diabetes drug.

In the trial, researchers said those taking rimonabant saw an average decrease in their HbA1c level of 0.8 compared to 0.3 for those on a placebo, with 51 percent of those on Acomplia (rimonabant) achieving the treatment target level recommended by the American Diabetes Association

Посмотрите также

• NICE Recommends Acomplia Be Available Through Britain’s National Health Service
  Sanofi-Aventis received a rare piece of good news about diet drug Acomplia (rimonabant) on March 26th when Britain’s National Institute for Health and Clinical Excellence (NICE) recommended that the diet pill be made available to obese and overweight patients through the U.K.’s National Health Service. NICE assesses the cost-effectiveness of treatments for [...]
• Zimulti Acomplia News — Oct. 2007 — News About Rimonabant
  Diet Drug Taranabant Yields Encouraging Results With ‘Generally Mild’ Side-Effects Taranabant, which a year from now may have surged past (Acomplia) rimonabant as the world’s most eagerly awaited diet drug, made a low-key debut Oct. 24th when researchers reported that participants in a clinical trial achieved encouraging weight loss with [...]
• Sanofi-Aventis Seeks to Shut Down News Coverage by the Acomplia Report
  Sanofi-Aventis, developer of the much touted diet drug Acomplia (rimonabant) , has announced its intention to try and shut down the independent Acomplia Report, denying hundreds of thousands of obese and overweight individuals this unbiased source of news about the drug and efforts to bring it to market. In emails [...]
• Diet Drug Acomplia Sales Disappoint; No Major Improvement Seen Until 2009
  Sales of diet drug Acomplia (rimonabant) , available in Europe but not approved in the U.S., have turned into a major disappointment for Sanofi-Aventis, which says it does not expect the situation to significantly improve until new clinical trial results are ready for submission to regulators in 2009. “ I [...]
• 
  Diet drug r Acomplia (rimonabant)  was approved for sale on April 3rd by Switzerland for treatment of obese or overweight patients with at least one type of associated cardiovascular risk. The approval by Switzerland, which is not a member of the European Union, is similar to the EU marketing approval [...]
• Sanofi Holds Little Hope For Early U.S. Sale of Acomplia / Zimulti (Rimonabant)
  Diet drug Acomplia / Zimulti ( rimonabant ) has now been taken by more than 200,000 obese and overweight patients in Europe and a handful of other countries, but Sanofi-Aventis offered no encouragement on Aug. 1 to those hoping to see it approved for early sale in the United States Rimonabant [...]

If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.

Powered by "ocomplia"
Copyright 2007. News Acomplia Zimulti. All rights reserved

• Home
• Sitemap